Safety of high-dose daptomycin in patients with severe renal impairment

Autor:	Chen-You Chen, Chi-Hao Shao, Chih-Hsun Tai, Chien-Chih Wu, Shu-Wen Lin
Rok vydání:	2018
Předmět:	safety renal impairment 0301 basic medicine medicine.medical_specialty Therapeutics and Clinical Risk Management daptomycin medicine.medical_treatment 030106 microbiology Population Gastroenterology 03 medical and health sciences Internal medicine Medicine Pharmacology (medical) Renal replacement therapy General Pharmacology Toxicology and Pharmaceutics education Original Research education.field_of_study Chemical Health and Safety biology business.industry Incidence (epidemiology) Retrospective cohort study General Medicine medicine.disease Bacteremia rhabdomyolysis biology.protein Creatine kinase Daptomycin business Safety Research Rhabdomyolysis medicine.drug
Zdroj:	Therapeutics and Clinical Risk Management
ISSN:	1178-203X
DOI:	10.2147/tcrm.s159587
Popis:	Chih-Hsun Tai,1 Chi-Hao Shao,2 Chen-You Chen,2 Shu-Wen Lin,1–3 Chien-Chih Wu1,2 1Department of Pharmacy, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; 3Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan Background: Treatment options are limited for infections due to multidrug-resistant Gram-positive pathogens. Daptomycin is a lipopeptide antibiotic with concentration-dependent killing characteristic and dose-dependent post-antibiotic effect. To achieve optimized pharmacodynamic effect, some experts advocated using a high dose of daptomycin (≥9 mg/kg) for severe infections. However, the safety of high-dose therapy in patients with renal impairment remains unknown. This study was aimed to evaluate the safety of daptomycin in patients with severe renal impairment. Methods: This was a retrospective study performed by reviewing electronic medical records. Patients with severe renal impairment who were treated with daptomycin in a tertiary teaching hospital between January 1, 2013, and June 30, 2016, were included for evaluation. The incidence rates of creatine kinase (CK) elevation between high-dose (≥9 mg/kg) and standard-dose (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf5774d6c8b51913200926df3659380 https://doi.org/10.2147/tcrm.s159587 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.